Content of nuclear transcription factor NF-kB in blood serum of patients with squamous cell cancer of the head and neck in the dynamics of accelerated radiation therapy with radiomodifiers
Open Access
- 30 June 2026
- journal article
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 34 (2) , 187-197
Abstract
Background. Radiation therapy is one of the main treatments for squamous cell carcinoma of the head and neck; however, tumor radioresistance often hinders treatment efficacy. Among the biomarkers associated with radiation resistance, the nuclear transcription factor NF-kB deserves special mention; it is one of the most versatile cellular regulators, playing a crucial role in cell proliferation, apoptosis, angiogenesis, and inflammation, as it regulates the expression of genes involved in these processes. NF-kB expression in tumors correlates with the response to radiation therapy with radiomodifiers, particularly with COX-2 inhibitors and cisplatin. Therefore, studying the level of this transcription factor in patients with advanced gastric cancer during radiation therapy with radiomodifiers is relevant and important.Purpose – to determine the serum NF-kB levels in patients with squamous cell carcinoma of the head and neck during accelerated radiotherapy with radiomodifiers (celecoxib, cisplatin, or a combination thereof) and to investigate the relationship between objective response to treatment and NF-kB expression.Materials and Methods. Thirty-seven patients with HNSCC aged 42–85 years (median age 66 years) were examined and treated. A general clinical examination was performed on all patients, and squamous cell carcinoma was morphologically confirmed by biopsy according to histological classification. The study included patients with stages I–IV disease. The level of NF-kB1 (p105 → p50) was determined in the serum of patients with SCLC using an ELISA assay with standard reagent kits. Measurements were performed using the Immunochem-2100 semiautomated enzyme-linked immunosorbent assay analyzer (USA). To determine NF-kB levels, blood samples were collected from patients before and after radiation therapy.Results. It has been shown that with various RT regimens using cisplatin and celecoxib, a decrease in NF-kB levels is observed in most patients with squamous cell carci-noma of the head and neck, which changes significantly 1.8-fold under the combined effect of accelerated radiotherapy and both modulators against the background of an increase in the number of regressions to 90%, which indicates the efficacy of this treatment regimen. It was established that changes in NF-kB levels correlate with the results of the objective response to treatment, which was used to assess the direct effect of radiation therapy (regression, stabilization, progression). During tumor regression, a decrease in NF-kB levels is observed, most pronounced with RT in combination with cisplatin and celecoxib. During tumor progression, no significant decrease in NF-kB was noted in any group, which is an unfavorable sign and may be associated with tumor resistance to the administered therapy.Conclusions. The use of a COX-2 inhibitor and cisplatin as radiosensitizers in combination with RT offers a new opportunity to improve the efficacy of radiation therapy for squamous cell carcinoma of the head and neck.Keywords
This publication has 14 references indexed in Scilit:
- Cancer statistics, 2025CA: A Cancer Journal for Clinicians, 2025
- INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMAExperimental Oncology, 2024
- NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targetsEuropean Journal of Medical Research, 2024
- The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwideInternational Journal of Cancer, 2024
- Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancersDrug Resistance Updates, 2024
- Effect of radiotherapy interruption on nasopharyngeal cancerFrontiers in Oncology, 2023
- Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancerFrontiers in Immunology, 2023
- Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cellsFrontiers in Oncology, 2023
- NF‐κB signaling in inflammation and cancerMedcomm, 2021
- Epidermal growth factor‐induced COX‐2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin‐like 4Cancer Science, 2020